Feasibility evaluation of N-Isopropyl Acrylamide 3D gel dosimeters for proton therapy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
05
2023
accepted:
30
08
2023
medline:
14
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
This study aimed to investigate the feasibility of applying 3D gel dosimeters for proton therapy. Two different formulations (5-5-3-5, 5-3-3-10) for the N-Isopropyl Acrylamide (NIPAM) polymer gel were used to find the best composition for the application of NIPAM polymer gels for proton therapy. The reaction of the gel under different physical conditions, including dependence on energy and dependence on the dose rate of the NIPAM gel under proton irradiation, was also explored. A NIPAM gel dosimeter was used to record the 3D dose distribution, and a self-developed parallel beam optical computed tomography scanner was used to obtain non-irradiated and post-irradiated gel phantom images. The NIPAM gel was filled into a cylindrical acrylic phantom. The results showed that the optical density of the irradiated NIPAM dosimeter was linear in the dose range of 0 to 6 Gy, and the linearity of the two NIPAM gel formulations at the depth of the dose point (2 cm) was 0.98 to 0.89. The dose depth curves showed different patterns with different gel sensitivities. This study demonstrated that the NIPAM gel dosimeter with the 5-3-3-10 formulation is suitable for verifying the dosimetry dose of proton beams.
Identifiants
pubmed: 37699042
doi: 10.1371/journal.pone.0291507
pii: PONE-D-23-12475
pmc: PMC10497135
doi:
Substances chimiques
Protons
0
N-isopropylacrylamide
B7GFF17L9U
Acrylamides
0
Gels
0
Polymers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291507Informations de copyright
Copyright: © 2023 Yao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Phys Med Biol. 2010 Mar 7;55(5):R1-63
pubmed: 20150687
Phys Med Biol. 2004 Sep 7;49(17):3847-55
pubmed: 15470909
Phys Med Biol. 2010 May 21;55(10):N291-301
pubmed: 20427858
Appl Radiat Isot. 2009 Mar;67(3):415-8
pubmed: 18691895
Phys Med Biol. 2017 Feb 21;62(4):N73-N89
pubmed: 28134130
Adv Drug Deliv Rev. 2017 Jan 15;109:26-44
pubmed: 27919760
J Phys Conf Ser. 2010;250(1):12035
pubmed: 21218172
Med Phys. 2010 May;37(5):2145-52
pubmed: 20527548
Phys Med Biol. 2000 Apr;45(4):859-78
pubmed: 10795977
Phys Med Biol. 2015 Apr 21;60(8):R155-209
pubmed: 25803097
Acta Oncol. 2011 Aug;50(6):829-34
pubmed: 21767181
PLoS One. 2012;7(10):e44905
pubmed: 23077487
Med Phys. 2001 Nov;28(11):2379-86
pubmed: 11764046
PLoS One. 2019 Feb 21;14(2):e0212546
pubmed: 30789968
Med Phys. 2003 Jun;30(6):1235-40
pubmed: 12852548
Phys Med Biol. 2006 Jul 21;51(14):3301-14
pubmed: 16825731